A detailed history of Act Capital Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Act Capital Management, LLC holds 58,300 shares of KRYS stock, worth $10.3 Million. This represents 5.61% of its overall portfolio holdings.

Number of Shares
58,300
Previous 59,000 1.19%
Holding current value
$10.3 Million
Previous $3.87 Million 4.9%
% of portfolio
5.61%
Previous 5.42%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022

SELL
$64.85 - $82.4 $45,394 - $57,680
-700 Reduced 1.19%
58,300 $4.06 Million
Q4 2021

Feb 03, 2022

BUY
$39.81 - $88.24 $756,390 - $1.68 Million
19,000 Added 47.5%
59,000 $4.13 Million
Q3 2021

Nov 16, 2021

BUY
$52.01 - $71.77 $1.09 Million - $1.5 Million
20,925 Added 109.7%
40,000 $2.09 Million
Q2 2021

Aug 16, 2021

BUY
$62.14 - $81.82 $1.19 Million - $1.56 Million
19,075 New
19,075 $1.3 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.55B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Act Capital Management, LLC Portfolio

Follow Act Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Act Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Act Capital Management, LLC with notifications on news.